20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Bright Minds Biosciences Inc (DRUG) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 26 employees. Its market capitalization is roughly $542 million. In the fiscal year ended 2025-09-30, DRUG reported C$0M in revenue and (C$12M) in net income.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | — |
| Gross Profit | C$0M | C$0M | — | C$0M | C$0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | (C$40M) | (C$14M) | (C$3M) | (C$7M) | (C$15M) | (C$9M) | C$0M | C$0M |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | (C$25M) | (C$12M) | (C$3M) | (C$7M) | (C$15M) | (C$9M) | C$0M | C$0M |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | (C$34M) | (C$12M) | (C$3M) | (C$7M) | (C$15M) | (C$9M) | C$0M | C$0M |
| Earnings Per Share (EPS) | C$-2.90 | C$-1.78 | C$-0.65 | C$-1.98 | C$-6.06 | C$-4.74 | C$-0.38 | C$-0.18 |
| Shares Outstanding (M) | 10M | 7M | 4M | 4M | 2M | 2M | 1M | 1M |
CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M |
| Gross Profit | C$0M | C$0M | C$0M | C$0M | C$0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | (C$12M) | (C$16M) | (C$7M) | (C$6M) | (C$3M) | (C$3M) | (C$2M) | (C$1M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | (C$2M) | (C$11M) | (C$8M) | (C$4M) | (C$5M) | (C$3M) | C$0M | (C$1M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | (C$12M) | (C$11M) | (C$8M) | (C$4M) | (C$5M) | (C$3M) | C$0M | (C$1M) |
| Earnings Per Share (EPS) | C$-0.25 | C$-1.11 | C$-0.97 | C$-0.57 | C$-0.74 | C$-0.63 | C$0.01 | C$-0.17 |
| Shares Outstanding (M) | 10M | 10M | 8M | 7M | 7M | 5M | 5M | 5M |
CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | (C$25M) | (C$9M) | (C$2M) | (C$7M) | (C$14M) | (C$7M) | C$0M | C$0M |
| Capital Expenditures (CapEx) | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M |
| Free Cash Flow (FCF) | (C$25M) | (C$9M) | (C$2M) | (C$7M) | (C$14M) | (C$7M) | C$0M | C$0M |
| FCF Margin % | — | — | — | — | — | — | — | — |
CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | (C$8M) | (C$9M) | (C$6M) | (C$1M) | (C$4M) | (C$2M) | (C$1M) | C$0M |
| Capital Expenditures (CapEx) | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M |
| Free Cash Flow (FCF) | (C$8M) | (C$9M) | (C$6M) | (C$1M) | (C$4M) | (C$2M) | (C$1M) | C$0M |
| FCF Margin % | — | — | — | — | — | — | — | — |
CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | C$311M | C$84M | C$6M | C$7M | C$12M | C$20M | C$1M | C$0M |
| Cash & Cash Equivalents | C$308M | C$83M | C$6M | C$7M | C$12M | C$20M | C$1M | C$0M |
| Total Liabilities | C$3M | C$2M | C$1M | C$0M | C$2M | C$1M | C$0M | C$0M |
| Total Debt (Short + Long-Term) | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M | C$0M |
| Total Shareholders' Equity | C$308M | C$82M | C$6M | C$7M | C$11M | C$19M | C$1M | C$0M |
CAD; C$M / C$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DRUG viewer.
About TickerBase · Data methodology & sources · Privacy · Terms